Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Shin Poong Seeks EMEA Special Approval For Anti-malarial Drug Pyramax

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Local South Korean drug maker Shin Poong Pharmaceutical submitted a new drug application to the European Medicines Agency for its new artemisinin combination therapy Pyramax (pyronaridine-artesunate) for malaria
Advertisement

Related Content

Korea’s Shin Poong Pharmaceutical Cuts Biotech Deal With France’s LFB Biotechnologies
Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers
Growing Malaria Resistance In Southeast Asia Sparks Public-Private Groups To Seek Answers
WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines
WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines
Advertisement
UsernamePublicRestriction

Register

SC074581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel